Acrivon Therapeutics, Inc. Common Stock
NASDAQ Global MarketTotal Valuation
Acrivon Therapeutics, Inc. Common Stock carries a market capitalization of 49.54M, placing it among publicly traded companies globally. Its enterprise value stands at -41.69M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 49.54M |
| Enterprise Value | -41.69M |
Share Statistics
Acrivon Therapeutics, Inc. Common Stock currently has 38.75M shares outstanding.
| Shares Outstanding | 38.75M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.18 |
| P/TBV Ratio | 0.56 |
| P/FCF Ratio | -0.85 |
| P/OCF Ratio | -0.83 |
Financial Position
Acrivon Therapeutics, Inc. Common Stock maintains a current ratio of 8.98, meaning it holds 9.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.98 |
| Quick Ratio | 8.84 |
| Debt / Equity | 2.53 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -54.38 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Acrivon Therapeutics, Inc. Common Stock's stock has gained approximately 35.34483% over the past 52 weeks. The 50-day moving average sits at 1.72, while the 200-day moving average is 1.85.
| Beta (5Y) | N/A |
| 52-Week Price Change | 35.34483% |
| 50-Day Moving Average | 1.72 |
| 200-Day Moving Average | 1.85 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -80.93M, while operating income came in at -82.35M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -82.35M |
| Pretax Income | -77.27M |
| Net Income | -77.27M |
| EBITDA | -80.93M |
| EBIT | -82.35M |
| Earnings Per Share (EPS) | -2.00 |
Balance Sheet
Acrivon Therapeutics, Inc. Common Stock holds 97.74M in cash and equivalents against 2.42M in total debt, resulting in a net debt position of -34.06M. Total book value stands at -293.88M, with working capital of 88.17M providing operational flexibility.
| Cash & Cash Equivalents | 97.74M |
| Total Debt | 2.42M |
| Net Debt | -34.06M |
| Equity (Book Value) | -293.88M |
| Book Value Per Share | -7.62 |
| Working Capital | 88.17M |
Cash Flow
Acrivon Therapeutics, Inc. Common Stock produced -64.67M in operating cash flow over the past twelve months. After subtracting -1.62M in capital expenditures, free cash flow totaled -66.29M - equivalent to -1.72 per share.
| Operating Cash Flow | -64.67M |
| Capital Expenditures | -1.62M |
| Free Cash Flow | -66.29M |
| FCF Per Share | -1.72 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.82 |
| FCF Yield | -117.55 |
Scores
Acrivon Therapeutics, Inc. Common Stock posts an Altman Z-Score of -2.74, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.74 |